UPDATE 1-Grifols sees plasma demand growing, prices stable

* 9-mth net profit 117 mln eur, meets analyst forecasts

* Sales 689.6 mln euros, up 15 pct on strong demand

* Shares up 0.13 percent

(Adds comments from director, analyst, shares)

By Tracy Rucinski and Jose Rodriguez

MADRID, Nov 4 (Reuters) - Spanish healthcare company Grifols
(GRLS.MC) sees continuing growing demand for blood plasma
products and stable prices after posting a 26 percent rise in
nine-month net profit, a director said on Wednesday.

While the economic and financial crisis has crippled
production in most sectors across the world, plasma -- the raw
material used for hemeoderivative products made by Grifols --
has continued to grow.

"Our perception in the hemeoderivative market is that demand
is still growing," Nuria Pascual, Investor Relations Director,
told Reuters in a telephone interview.

Pascual also predicted prices would remain stable, saying
the company -- which competes with Baxter (BAX.N) and
Australia's CSL (CSL.AX) -- had not noticed any downward
pressure.

Earlier, Grifols posted net profit of 117 million euros, in
line with analyst forecasts. [ID:nL2422819]

The numbers helped ease concerns sparked by quarterly
earnings last month by Baxter and CSL. [ID:nN15287738]
[ID:nSYD538163]

"These are quality results, supported by the company's most
important division: bioscience. We think the numbers should help
ease some doubts and allow the share price to regain some lost
territory over the past month," Luis Blas, Banesto Bolsa analyst
said in a note.

Grifols stock, which has lost 12 percent over the past
month, was up 0.13 percent by 1625 GMT, compared with a 1.1
percent gain on Spain's blue chip index .IBEX.

(Reporting by Tracy Rucinski, Jose Rodriguez; Editing by
Elaine Hardcastle)